GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
09 déc. 2024 09h00 HE
|
GeoVax, Inc.
Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and...
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
26 nov. 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its...
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
19 nov. 2024 09h00 HE
|
GeoVax, Inc.
GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines...
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h00 HE
|
GeoVax, Inc.
Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19 vaccine Phase 2 trials expected during fourth quarter 2024 Gedeptin® on track to advance...
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
05 nov. 2024 09h00 HE
|
GeoVax, Inc.
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines...
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
02 oct. 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that...
GeoVax to Participate in Upcoming Investor Conferences in September
03 sept. 2024 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today...
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
28 août 2024 20h59 HE
|
GeoVax, Inc.
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious...
Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO
21 août 2024 09h00 HE
|
GeoVax, Inc.
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax...
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
20 août 2024 07h45 HE
|
GeoVax, Inc.
ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious...